uploads/2016/06/Part-3-Graph-06-08-16-1.png

Agios Stock Rises on Higher Trading Volumes on June 8

By

Updated

Agios moves up

On June 8, Agios Pharmaceuticals (AGIO) was the biggest gainer in the mid-cap space of the SPDR S&P Biotech ETF (XBI). AGIO rose by 7.3% and outperformed the SPDR S&P 500 ETF (SPY).

On the other hand, Intrexon (XON) underperformed the most within XBI and fell by 7.4%. Please read Part 1 of this series for further details.

Article continues below advertisement

Agios’s trends

Agios (AGIO) rose on higher trading volumes, although there was no specific reason for its upward movement. Approximately 1.4 million shares were traded compared to its three-month average trading volume of ~686,000 shares per day.

Agios is up by 1.8% on a year-to-date basis. Approximately 19.6% of its total outstanding shares are short. Agios’s 52-week low is $33.50, and its 52-week high is $124.12. The relative strength index (or RSI) of Agios is 67, indicating that the stock is moving toward an overbought situation.

Agios has a book value of $8.77 per share. At its current price, the stock is trading at a price-to-book value of ~7.5x. Among Agios’s mid-caps peers, Ligand Pharmaceuticals (LGND), Myriad Genetics (MYGN), and Juno Therapeutics (JUNO) are trading at price-to-book values of 6.3x, 3.2x, and 4.1x, respectively, which is lower than Agios’s price-to-book value.

Analyst recommendations and estimates

The analyst consensus expects Agios’s (AGIO) 12-month target to be $56.50, representing a return potential of -14.5%. Three analysts recommended a “buy” for the stock, eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.

Advertisement

More From Market Realist